Martin Farlow

Summary

Affiliation: Indiana University
Country: USA

Publications

  1. ncbi High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial
    Paul S Aisen
    Department of Neurosciences, University of California, San Diego, 9500 Gilman Dr, M C 0949, La Jolla, CA 92093, USA
    JAMA 300:1774-83. 2008
  2. ncbi Etiology and pathogenesis of Alzheimer's disease
    M R Farlow
    Department of Neurology, School of Medicine, Indiana University, Indianapolis 46202 5111, USA
    Am J Health Syst Pharm 55:S5-10. 1998
  3. ncbi Effects of oral rivastigmine on cognitive domains in mild-to-moderate Alzheimer's disease
    Martin R Farlow
    Indiana University School of Medicine, Indianapolis, USA
    Am J Alzheimers Dis Other Demen 25:347-52. 2010
  4. ncbi Effective pharmacologic management of Alzheimer's disease
    Martin R Farlow
    Department of Neurology, Indiana University School of Medicine, Indianapolis 46202 5111, USA
    Am J Med 120:388-97. 2007
  5. ncbi Differential qualitative responses to rivastigmine in APOE epsilon 4 carriers and noncarriers
    M Farlow
    Department of Neurology, Indiana University School of Medicine, Indianapolis, IN, USA
    Pharmacogenomics J 4:332-5. 2004
  6. ncbi Impact of APOE in mild cognitive impairment
    M R Farlow
    Department of Neurology, Indiana University School of Medicine, Clinical Building, Room 299, 541 Clinical Drive, Indianapolis, IN 46202 5111, USA
    Neurology 63:1898-901. 2004
  7. ncbi Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years
    Martin R Farlow
    Department of Neurology, Indiana University, Indianapolis, Indiana, USA
    BMC Geriatr 5:3. 2005
  8. ncbi Utilizing combination therapy in the treatment of Alzheimer's disease
    Martin R Farlow
    Department of Neurology, Indiana University School of Medicine, CL 299, 541 Clinical Drive, Indianapolis, IN 46202 5111, USA
    Expert Rev Neurother 4:799-808. 2004
  9. ncbi A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis
    Martin R Farlow
    Department of Neurology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Curr Med Res Opin 26:263-9. 2010
  10. ncbi Use of antidementia agents in vascular dementia: beyond Alzheimer disease
    Martin R Farlow
    Department of Neurology, Indiana University School of Medicine, CL 299, 541 Clinical Dr, Indianapolis, IN 46202, USA
    Mayo Clin Proc 81:1350-8. 2006

Detail Information

Publications70

  1. ncbi High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial
    Paul S Aisen
    Department of Neurosciences, University of California, San Diego, 9500 Gilman Dr, M C 0949, La Jolla, CA 92093, USA
    JAMA 300:1774-83. 2008
    ..Prior studies of B vitamins to reduce homocysteine in AD have not had sufficient size or duration to assess their effect on cognitive decline...
  2. ncbi Etiology and pathogenesis of Alzheimer's disease
    M R Farlow
    Department of Neurology, School of Medicine, Indiana University, Indianapolis 46202 5111, USA
    Am J Health Syst Pharm 55:S5-10. 1998
    ..The etiology and pathogenesis of AD are highly complex; more effective therapeutic approaches than those currently available will be needed to address these underlying factors more specifically...
  3. ncbi Effects of oral rivastigmine on cognitive domains in mild-to-moderate Alzheimer's disease
    Martin R Farlow
    Indiana University School of Medicine, Indianapolis, USA
    Am J Alzheimers Dis Other Demen 25:347-52. 2010
    ..Evaluation of ADAS-cog domain scores provides insight into test items most likely to respond to treatment...
  4. ncbi Effective pharmacologic management of Alzheimer's disease
    Martin R Farlow
    Department of Neurology, Indiana University School of Medicine, Indianapolis 46202 5111, USA
    Am J Med 120:388-97. 2007
    ....
  5. ncbi Differential qualitative responses to rivastigmine in APOE epsilon 4 carriers and noncarriers
    M Farlow
    Department of Neurology, Indiana University School of Medicine, Indianapolis, IN, USA
    Pharmacogenomics J 4:332-5. 2004
    ..48 points. Thus, non-APOE epsilon4 carriers showed a less favorable course under either placebo or rivastigmine, but both genotype-defined subgroups showed quantitatively similar responses to therapy (both P<0.05 vs placebo)...
  6. ncbi Impact of APOE in mild cognitive impairment
    M R Farlow
    Department of Neurology, Indiana University School of Medicine, Clinical Building, Room 299, 541 Clinical Drive, Indianapolis, IN 46202 5111, USA
    Neurology 63:1898-901. 2004
    ..The authors aimed to use baseline data of an ongoing large, prospective study in subjects with mild cognitive impairment (MCI) to investigate the impact of APOE genotype on the symptom profile of the condition...
  7. ncbi Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years
    Martin R Farlow
    Department of Neurology, Indiana University, Indianapolis, Indiana, USA
    BMC Geriatr 5:3. 2005
    ..The purpose of this report is to present safety and effectiveness data for rivastigmine therapy in patients with mild to moderately severe AD receiving treatment for up to 5 years...
  8. ncbi Utilizing combination therapy in the treatment of Alzheimer's disease
    Martin R Farlow
    Department of Neurology, Indiana University School of Medicine, CL 299, 541 Clinical Drive, Indianapolis, IN 46202 5111, USA
    Expert Rev Neurother 4:799-808. 2004
    ..This review evaluates the available data on combination therapy in Alzheimer's disease and provides an expert opinion on the use and implementation of combination therapy in clinical practice...
  9. ncbi A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis
    Martin R Farlow
    Department of Neurology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Curr Med Res Opin 26:263-9. 2010
    ..To investigate the tolerability and efficacy of the rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease receiving concomitant memantine...
  10. ncbi Use of antidementia agents in vascular dementia: beyond Alzheimer disease
    Martin R Farlow
    Department of Neurology, Indiana University School of Medicine, CL 299, 541 Clinical Dr, Indianapolis, IN 46202, USA
    Mayo Clin Proc 81:1350-8. 2006
    ..These data suggest that antidementia drugs currently used for treatment of AD should be considered for treatment of VaD as well...
  11. ncbi Treatment of mild cognitive impairment (MCI)
    M R Farlow
    Indiana University School of Medicine, Indianapolis, Indiana, USA
    Curr Alzheimer Res 6:362-7. 2009
    ....
  12. ncbi Efficacy of rivastigmine in Alzheimer's disease patients with rapid disease progression: results of a meta-analysis
    Martin R Farlow
    Indiana University School of Medicine, Indianapolis, IN 46202 5111, USA
    Dement Geriatr Cogn Disord 20:192-7. 2005
    ..In a recent retrospective analysis, treatment effects of rivastigmine were more pronounced in AD patients with rapid cognitive decline than in those with slow cognitive decline. This warranted further investigation...
  13. ncbi Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy
    Martin R Farlow
    Department of Neurology, Indiana University School of Medicine, Indianapolis, IN, USA
    Int J Geriatr Psychiatry 26:1236-43. 2011
    ..This exploratory, hypothesis-forming analysis assessed response to rivastigmine according to severity of dementia at baseline...
  14. ncbi Memantine for the treatment of Alzheimer's disease: tolerability and safety data from clinical trials
    Martin R Farlow
    Department of Neurology, Indiana University School of Medicine, Indianapolis, Indiana 46202 5111, USA
    Drug Saf 31:577-85. 2008
    ..The objective of this study was to analyse safety and tolerability data from phase III memantine trials and from the open-label extensions of those trials...
  15. ncbi Treatment options in Alzheimer's disease: maximizing benefit, managing expectations
    Martin R Farlow
    Indiana University School of Medicine, Indianapolis, Ind 46202 5111, USA
    Dement Geriatr Cogn Disord 25:408-22. 2008
    ....
  16. ncbi A modern hypothesis: The distinct pathologies of dementia associated with Parkinson's disease versus Alzheimer's disease
    Martin R Farlow
    Department of Neurology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Dement Geriatr Cogn Disord 25:301-8. 2008
    ..The aim of this review was to survey the recent literature on the pathology of PDD and compare the pathology of PDD to that of Alzheimer's disease (AD)...
  17. ncbi Should the ApoE genotype be a covariate for clinical trials in Alzheimer disease?
    Martin R Farlow
    Department of Neurology, Indiana University School of Medicine, 541 Clinical Drive, CL 291, Indianapolis, IN 46202, USA
    Alzheimers Res Ther 2:15. 2010
    ....
  18. ncbi Clinical pharmacokinetics of galantamine
    Martin R Farlow
    Department of Neurology, Indiana University School of Medicine, Indianapolis, Indiana 46202 5111, USA
    Clin Pharmacokinet 42:1383-92. 2003
    ..Based on the literature and clinical trial experience, galantamine appears to be an excellent treatment option for patients with Alzheimer's disease, vascular dementia or Alzheimer's disease with cerebrovascular disease...
  19. ncbi Pharmacokinetic profiles of current therapies for Alzheimer's disease: implications for switching to galantamine
    M R Farlow
    Department of Neurology, Indiana University School of Medicine, Indianapolis 46202 5111, USA
    Clin Ther 23:A13-24. 2001
    ..Benefits of this dual mode of action on the effects of the disease have been suggested...
  20. ncbi A clinical overview of cholinesterase inhibitors in Alzheimer's disease
    Martin Farlow
    Department of Neurology, Indiana University School of Medicine, Indianapolis, Indiana 46202 5111, USA
    Int Psychogeriatr 14:93-126. 2002
    ..As clinical and research experience with these agents continues to accumulate, the differences in their effects will become more apparent and will help physicians tailor ChE inhibition treatment to the needs of the individual patient...
  21. ncbi Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression
    M R Farlow
    Department of Neurology, Indiana University School of Medicine, CL583, 541 Clinical Dr, Indianapolis, IN 46202 5111, USA
    Arch Neurol 58:417-22. 2001
    ..Evidence suggests that disease severity predicts the response of patients with Alzheimer disease (AD) to cholinesterase inhibitor treatment, raising the question of whether disease progression also predicts response to this treatment...
  22. ncbi The ACTION study: methodology of a trial to evaluate safety and efficacy of a higher dose rivastigmine transdermal patch in severe Alzheimer's disease
    Martin R Farlow
    Department of Neurology, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    Curr Med Res Opin 26:2441-7. 2010
    ..Earlier studies have demonstrated the efficacy of rivastigmine in severe Alzheimer's disease (AD), and supported the use of a higher dose patch in AD...
  23. ncbi Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study
    Martin R Farlow
    Department of Neurology, Indiana University School of Medicine, Indianapolis, 46202, USA
    Clin Ther 32:1234-51. 2010
    ..We hypothesized that the loss of initial therapeutic benefit over time may be mitigated by higher doses of a cholinesterase inhibitor...
  24. ncbi A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease
    M Farlow
    Department of Neurology, Indiana University School of Medicine, Indianapolis, IN 46202 5111, USA
    Eur Neurol 44:236-41. 2000
    ..By 52 weeks, patients originally treated with 6-12 mg/day rivastigmine had significantly better cognitive function than patients originally treated with placebo...
  25. ncbi Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial
    Martin Farlow
    Department of Neurology, Indiana University School of Medicine, Indianapolis 46202, USA
    Arch Neurol 60:843-8. 2003
    ..Therefore, to evaluate the effect of discontinuing treatment, we analyzed the retrieved dropout (RDO) population...
  26. ncbi Metrifonate therapy in Alzheimer's disease: a pooled analysis of four randomized, double-blind, placebo-controlled trials
    M R Farlow
    Indiana University School of Medicine, Indianapolis, Ind 46202 5111, USA
    Dement Geriatr Cogn Disord 11:202-11. 2000
    ....
  27. ncbi Update on rivastigmine
    Martin R Farlow
    Department of Neurology, Indiana University School of Medicine, Indianapolis, IN 46202 5111, USA
    Neurologist 9:230-4. 2003
    ..Metabolism of rivastigmine occurs at the synapse rather than at the liver and previous studies have demonstrated no drug-drug interactions. Rivastigmine has a half-life at the synapse of 9 hours allowing for bid dosing...
  28. ncbi Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease
    Martin Farlow
    Department of Neurology, Indiana University School of Medicine, 541 Clinical Drive, CL299, Indianapolis, IN 46202, USA
    BMC Neurol 11:57. 2011
    ..This report, based on a pivotal phase 3 study, presents a detailed analysis of the safety and tolerability of increasing donepezil to 23 mg/d compared with continuing 10 mg/d...
  29. ncbi A commonly carried allele of the obesity-related FTO gene is associated with reduced brain volume in the healthy elderly
    April J Ho
    Laboratory of Neuroimaging, Department of Neurology, University of California School of Medicine, Los Angeles, CA 90095, USA
    Proc Natl Acad Sci U S A 107:8404-9. 2010
    ..These brain maps reveal that a commonly carried susceptibility allele for obesity is associated with structural brain atrophy, with implications for the health of the elderly...
  30. ncbi NMDA receptor antagonists. A new therapeutic approach for Alzheimer's disease
    Martin R Farlow
    Department of Neurology, Indiana University School of Medicine, Indianapolis, USA
    Geriatrics 59:22-7. 2004
    ....
  31. ncbi Voxelwise genome-wide association study (vGWAS)
    Jason L Stein
    Laboratory of Neuro Imaging, Department of Neurology, University of California, Los Angeles School of Medicine, Neuroscience Research Building 225E, 635 Charles Young Drive, Los Angeles, CA 90095 1769, USA
    Neuroimage 53:1160-74. 2010
    ..These genes have high relevance to brain structure. This is the first voxelwise genome wide association study to our knowledge, and offers a novel method to discover genetic influences on brain structure...
  32. ncbi Whole genome association study of brain-wide imaging phenotypes for identifying quantitative trait loci in MCI and AD: A study of the ADNI cohort
    Li Shen
    Center for Neuroimaging, Department of Radiology and Imaging Sciences, Indiana University School of Medicine, 950 West Walnut Street R2 E124, Indianapolis, IN 46202, USA
    Neuroimage 53:1051-63. 2010
    ..A genome-wide, whole brain search strategy has the potential to reveal novel candidate genes and loci warranting further investigation and replication...
  33. ncbi Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer's disease
    David A Wolk
    Department of Neurology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Proc Natl Acad Sci U S A 107:10256-61. 2010
    ....
  34. ncbi Genome-wide association study of CSF biomarkers Abeta1-42, t-tau, and p-tau181p in the ADNI cohort
    S Kim
    Center for Neuroimaging, Department of Radiology and Imaging Sciences, Indiana University School of Medicine, 950 West Walnut Street, R2 E124, Indianapolis, IN 46202, USA
    Neurology 76:69-79. 2011
    ..We report a genome-wide association study (GWAS) of CSF biomarkers (A?1-42, t-tau, p-tau181p, p-tau181p/A?1-42, and t-tau/A?1-42)...
  35. ncbi Randomized clinical trial results for donepezil in Alzheimer's disease: is the treatment glass half full or half empty?
    Martin R Farlow
    Department of Neurology, Indiana University School of Medicine, Indianapolis, IN, USA
    J Am Geriatr Soc 56:1566-7. 2008
  36. ncbi Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease
    Richard Dodel
    Department of Neurology, Philipps University Marburg, Germany
    Ann Neurol 52:253-6. 2002
    ..This study provides evidence that intravenous immunoglobulin or purified Abeta antibodies may modify Abeta and Abeta(1-42) levels, suggesting potential utility as a therapy for Alzheimer disease...
  37. ncbi Human anti-beta-amyloid antibodies block beta-amyloid fibril formation and prevent beta-amyloid-induced neurotoxicity
    Yansheng Du
    Department of Neurology, School of Medicine, Indiana University, 975 W Walnut Street IB 457, Indianapolis, IN 46202, USA
    Brain 126:1935-9. 2003
    ....
  38. ncbi In vivo and postmortem clinicoanatomical correlations in frontotemporal dementia and parkinsonism linked to chromosome 17
    Bernardino Ghetti
    Indiana Alzheimer Disease Center, Indiana University School of Medicine, Indianapolis, Ind 46202, USA
    Neurodegener Dis 5:215-7. 2008
    ..Despite the differences, FTDP-17T and FTDP-17U share a largely overlapping clinical phenotype...
  39. ncbi Depressed mood in informal caregivers of individuals with mild cognitive impairment
    Yueh Feng Yvonne Lu
    Indiana University School of Nursing, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Am J Alzheimers Dis Other Demen 22:273-85. 2007
    ..Controlling for relevant variables, relational deprivation and caregiver education continued to be significantly associated with depressed mood. Relational deprivation may be important for future interventions...
  40. ncbi A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease
    Debomoy K Lahiri
    Department of Psychiatry and Neurology, Institute of Psychiatric Research, Indiana University School of Medicine, Indianapolis, IN 46202 4887, USA
    Curr Drug Targets 4:97-112. 2003
    ..All these current research efforts should lead to a deeper understanding of the pathobiochemical processes that occur in the AD brain in order to effectively diagnose and prevent their occurrence...
  41. ncbi On the horizon: pathways for drug development in Alzheimer's disease
    Ann Marie Hake
    Department of Neurology, Indiana University School of Medicine, 541 Clinical Drive, Suite 299, Indianapolis, IN 46202, USA
    Clin Geriatr Med 20:141-52. 2004
  42. ncbi High levels of Alzheimer beta-amyloid precursor protein (APP) in children with severely autistic behavior and aggression
    Deborah K Sokol
    Department of Neurology, Indiana University School of Medicine, 702 Barnhill Drive, Indianapolis, IN 46202, USA
    J Child Neurol 21:444-9. 2006
    ..This favors an increased alpha-secretase pathway in autism (anabolic), opposite to what is seen in Alzheimer disease. Additionally, a complex relationship between age, acetylcholinesterase, and plasma neuronal markers was found...
  43. ncbi Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial
    Paul S Aisen
    Department of Neurology, Georgetown University Medical Center, Washington, DC 20057, USA
    JAMA 289:2819-26. 2003
    ....
  44. ncbi The tauopathy associated with mutation +3 in intron 10 of Tau: characterization of the MSTD family
    Salvatore Spina
    Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Brain 131:72-89. 2008
    ..This multidisciplinary study provides a comprehensive description of the natural history of disease in one of the largest known families with FTDP-17T...
  45. ncbi Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer's disease: a meta-analysis
    Noll Campbell
    Wishard Health Services, Indianapolis, Indiana, USA
    Clin Interv Aging 3:719-28. 2008
    ..To determine the efficacy of cholinesterase inhibitors (ChEIs) in improving the behavioral and psychological symptoms of dementia (BPSD) in patients with Alzheimer's disease (AD)...
  46. ncbi Implementing innovative models of dementia care: The Healthy Aging Brain Center
    Malaz A Boustani
    Indiana University Center for Aging Research, Indianapolis, USA
    Aging Ment Health 15:13-22. 2011
    ..Recent randomized controlled trials have demonstrated the effectiveness of the collaborative dementia care model targeting both the patients suffering from dementia and their informal caregivers...
  47. ncbi Minocycline blocks 6-hydroxydopamine-induced neurotoxicity and free radical production in rat cerebellar granule neurons
    Suizhen Lin
    Department of Neurology, Indiana University School of Medicine, 975 West Walnut Street, Rm 457, Indianapolis, IN 46202, USA
    Life Sci 72:1635-41. 2003
    ..Both the antioxidative and neuroprotective effects of minocycline may be beneficial in the therapy of Parkinson's disease and other neurodegenerative diseases...
  48. ncbi Differences in medication use in the Alzheimer's disease neuroimaging initiative: analysis of baseline characteristics
    Noam U Epstein
    Indiana University School of Medicine, Indianapolis, 46202, USA
    Drugs Aging 27:677-86. 2010
    ..Many participants in the ADNI are being treated with medications, and these may have beneficial or deleterious effects...
  49. ncbi Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease
    Eric R Siemers
    Eli Lilly and Company, Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    Clin Neuropharmacol 33:67-73. 2010
    ..LY2062430 (solanezumab) is a humanized monoclonal antibody being studied as a putative disease-modifying treatment of AD...
  50. ncbi NF-(kappa)B mediates amyloid beta peptide-stimulated activity of the human apolipoprotein E gene promoter in human astroglial cells
    Yansheng Du
    Department of Neurology, Institute of Psychiatric Research, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Brain Res Mol Brain Res 136:177-88. 2005
    ..Our data provide evidence that upregulation of APOE by A(beta) in astroglial cells is mediated by an NF-(kappa)B-element present in the 5'-flanking region of the APOE gene...
  51. ncbi Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers
    Eric Siemers
    Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    Clin Neuropharmacol 28:126-32. 2005
    ..A dose-dependent reduction in plasma Abeta was demonstrated, and changes in plasma Abeta concentrations were temporally related to the pharmacokinetic characteristics of LY450139...
  52. ncbi C/T conversion alters interleukin-1A promoter function in a human astrocyte cell line
    Xing Wei
    Department of Neurology, Indiana University School of Medicine, 975 West Walnut Street, IB457, Indianapolis, IN 46202, USA
    Life Sci 80:1152-6. 2007
    ..Induced promoter activity by the polymorphism (T/T) may result in the upregulation of interleukin-1alpha protein and "cytokine cycle" amplification, which may promote disease development...
  53. ncbi NF-kappaB mediates IL-1beta-induced synthesis/release of alpha2-macroglobulin in a human glial cell line
    Feng Gao
    Department of Neurology, Indiana University School of Medicine, Indianapolis, IN 46285, USA
    Brain Res Mol Brain Res 105:108-14. 2002
    ..Our data suggest that attenuation of IL-1beta-induced alpha(2)M synthesis/release by blocking NF-kappaB activation may potentially be 'protective' against the development of late-onset AD...
  54. ncbi Caffeic acid phenethyl ester prevents neonatal hypoxic-ischaemic brain injury
    Xing Wei
    Department of Neurology, School of Medicine, Indiana University, Indianapolis, IN 46202, USA
    Brain 127:2629-35. 2004
    ..CAPE may therefore be a novel effective therapy for preventing neonatal HI injury...
  55. ncbi Strategies for continued successful treatment of Alzheimer's disease: switching cholinesterase inhibitors
    Serge Gauthier
    McGill Centre for Studies in Aging, Verdun, Quebec, Canada
    Curr Med Res Opin 19:707-14. 2003
    ..The panel also aimed to reach consensus on 'whom to switch', 'when to switch' and 'how to switch'. The key findings from that meeting are reported in this review...
  56. ncbi Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase
    Eric R Siemers
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285
    Clin Neuropharmacol 30:317-25. 2007
    ..gamma-Secretase inhibitors may be useful as disease-modifying drugs for the treatment of Alzheimer disease. LY450139 is a gamma-secretase inhibitor currently in clinical development, with doses being optimized through the use of biomarkers...
  57. ncbi Quantitative analysis of amyloid beta peptides in cerebrospinal fluid of Alzheimer's disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/negative electrospray ionization tandem mass spectrometry
    Tomoyuki Oe
    Centers for Cancer Pharmacology and Excellence in Environmental Toxicology, Departments of Pharmacology and Chemistry, University of Pennsylvania, Philadelphia, PA 19104-6160, USA
    Rapid Commun Mass Spectrom 20:3723-35. 2006
    ..Moreover, the introduction of stable isotope labeled internal standards offers the potential to achieve a more rigorous account of the influence of methodological effects related to sample collection and processing...
  58. ncbi A collaborative study of the emergence and clinical features of the major depressive syndrome of Alzheimer's disease
    George S Zubenko
    Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, Room E1230, 3811 O Hara Street, Pittsburgh, PA 15213, USA
    Am J Psychiatry 160:857-66. 2003
    ....
  59. ncbi Quantitative analysis of amyloid-beta peptides in cerebrospinal fluid using immunoprecipitation and MALDI-Tof mass spectrometry
    Valentina Gelfanova
    Integrative Biology Division, Lilly Research Laboratories, Greenfield, IN 46140, USA
    Brief Funct Genomic Proteomic 6:149-58. 2007
    ..Application of the MALDI-Tof assay to CSF obtained from healthy volunteers and Alzheimer's disease patients indicated statistically significant 43% lower levels of Abeta(1-42) in the AD group (P = 0.0025)...
  60. ncbi Recommendations for best practices in the treatment of Alzheimer's disease in managed care
    Howard M Fillit
    Alzheimer s Drug Discovery Foundation and Institute for the Study of Aging New York, New York 10019, USA
    Am J Geriatr Pharmacother 4:S9-S24; quiz S25-S28. 2006
    ..However, these clinical guidelines have not been updated in the past few years...
  61. ncbi Combination drug therapies for AD: progress is slow, but we must keep trying
    Martin R Farlow
    Geriatrics 60:13-4. 2005
  62. ncbi Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial
    Pierre N Tariot
    Department of Psychiatry, University of Rochester Medical Center, Monroe Community Hospital, Rochester, NY 14620, USA
    JAMA 291:317-24. 2004
    ....
  63. ncbi Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease
    Roger Lane
    Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936 1080, USA
    Pharmacogenet Genomics 18:289-98. 2008
    ..To evaluate the synergistic effects of the apolipoprotein E (APOE) epsilon4 and butyrylcholinesterase K-variant (BCHE-K) alleles on progression to Alzheimer's disease (AD) in individuals with mild cognitive impairment (MCI)...
  64. ncbi Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition
    Elaine R Peskind
    VA Puget Sound Health Care System, Mental Illness Research, Education, and Clinical Center, Seattle, WA 98108, USA
    Arch Neurol 63:936-9. 2006
    ..Normal aging and the presence of the apolipoprotein E (APOE*4) allele are the most important known risk factors for Alzheimer disease...
  65. ncbi Multiple SNPs within and surrounding the apolipoprotein E gene influence cerebrospinal fluid apolipoprotein E protein levels
    Lynn M Bekris
    Geriatric Research, Education, and Clinical Center GRECC, VA Puget Sound Health Care System, Seattle, WA 98108, USA
    J Alzheimers Dis 13:255-66. 2008
    ..Further investigation of the genetic influence of these loci on apoE expression levels in the central nervous system is likely to provide new insight into apoE regulation as well as AD pathogenesis...
  66. ncbi A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type
    Lon S Schneider
    Department of Psychiatry and the Behavioral Sciences, Keck School of Medicine, University of Southern California, Los Angeles, 90033, USA
    Curr Alzheimer Res 2:541-51. 2005
    ..Previous studies of Ginkgo biloba extract (GbE) in patients with various forms of cognitive impairment or dementia have shown promising results...
  67. ncbi Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease
    Adam S Fleisher
    University of California, San Diego, La Jolla, CA 92037, USA
    Arch Neurol 65:1031-8. 2008
    ..To evaluate the safety, tolerability, and amyloid beta (Abeta) response to the gamma-secretase inhibitor LY450139 in Alzheimer disease...
  68. ncbi Lipid homeostasis and apolipoprotein E in the development and progression of Alzheimer's disease
    Roger M Lane
    Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
    J Lipid Res 46:949-68. 2005
    ..This review examines the current evidence for diet, lipid homeostasis, and apoE in the pathogenesis of AD. Effects on the cholinergic system and response to cholinesterase inhibitors by APOE allele carrier status are discussed briefly...
  69. ncbi The use of memantine in dementia with Lewy bodies
    Marwan N Sabbagh
    The Cleo Roberts Center for Clinical Research, Sun Health Research Institute, Sun City, AZ 85351, USA
    J Alzheimers Dis 7:285-9. 2005
    ..To determine the effect of memantine in the treatment of Dementia with Lewy Bodies (DLB)...
  70. ncbi Safety and acceptability of the research lumbar puncture
    Elaine R Peskind
    VA Puget Sound Health Care System, Mental Illness Research, Education and Clinical Center MIRECC, University of Washington School of Medicine, Seattle, WA 98108, USA
    Alzheimer Dis Assoc Disord 19:220-5. 2005
    ....